AWARD-PEDS PLUS

Eli Lilly and Company / “A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less than 18 Years of Age with Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)”

A solid, uniform light blue color fills the entire image without any patterns, objects, or text visible.

Study Description

IRB #

H9X-MCG-BGS

NCT #

NCT06739122

Principal Investigator

Petter Bjornstad, MD

Study Location

Seattle Children’s Hospital

This study is being done to see how safe a study drug is and how well it will work to help people with type 2 diabetes mellitus (T2DM). The study will test dulaglutide (also called Trulicity®), which is approved in the US, European Union, China, and other countries and is available by prescription to treat T2DM in children and adults. It is given as an injection under the skin. This study will test 4.5 mg doses of dulaglutide in children. This dose has already been approved in adults, but not yet in children.

Study Details

FAQ AWARD-PEDS PLUS

Learn more about how you can contribute to important research by volunteering for AWARD-PEDS PLUS

Who Can Participate?

Youth between the ages of 12-25 with 1 diabetes, are not taking any diabetes control medications other than insulin, and have been steady on their insulin delivery system for 6 months.

Compensation Provided

You will be paid for your time. If you complete all study visits, you will be paid up to $900 as well as compensated for your travel and food expenses.

Contact Study Team

Interested? Complete form below to contact the study team!

Contact Name: Kevin Bocek

Phone Number: 206-884-1982

Email: kevin.bocek@seattlechildrens.org

Contact the Study Team - AWARD-PEDS PLUS

Name(Required)

First Last

Phone(Required)

Email(Required)

Enter Email Confirm Email

Comments(Required)

Preferred Method of Contact (email, phone call, text)